# Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

> **NCT01569412** · PHASE1,PHASE2 · TERMINATED · sponsor: **Krankenhaus Nordwest** · enrollment: 14 (actual)

## Conditions studied

- Her2/Neu Positive Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** Ertumaxomab

## Key facts

- **NCT ID:** NCT01569412
- **Lead sponsor:** Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569412, "Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01569412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*